SEC Form 4 · accession 0001209191-18-005220
AMICUS THERAPEUTICS, INC. · FOLD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Bradley L Campbell
Officer — Chief Operating Officer
Period of report
Jan 22, 2018
Accepted (ET)
Jan 24, 2018 · 5:59 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178879
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 22, 2018 | M | 32,500 | $10.21 | A | 186,600 | D | |
| Common StockF2 | Jan 22, 2018 | S | 32,500 | $15.9191 | D | 154,100 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (right to buy)F3 | $10.21 | Jan 22, 2018 | M | 32,500 | D | — | Feb 5, 2018 | Common Stock | 32,500 | 0 | D |
Explanation of responses
- F1The sales of shares of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2017.
- F2This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $15.73 to $16.24. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3All of the options were fully vested and exercisable as of January 22, 2018.
Remarks
The options exercised were issued to Mr. Campbell in February 2008 and these options would have expired in February 2018.